Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Astatine-211 radiolabelled girentuximab - ATONCO Pharma

Next Previous
Drug Profile

Astatine-211 radiolabelled girentuximab - ATONCO Pharma

Alternative Names: 211At-TLX250; [211At]At-Girentuximab; [²¹¹At]At-anti-CA-IX antibody; ATO-101

Latest Information Update: 28 Jan 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Telix Pharmaceuticals
  • Class Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies; Radioisotopes; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Bladder cancer

Most Recent Events

  • 15 Dec 2025 Preclinical trials in Bladder cancer in France (Intravesicular)
  • 15 Dec 2025 Institut Cancerologie de l'Ouest in collaboration with Atonco Pharma plans a phase I PERSEVERANCE trial for Bladder cancer (Second line therapy or greater) in France (Intravesical) in February 2026 (NCT07260162)
  • 31 Mar 2025 Pharmacodynamics data from preclinical studies in Bladder cancer released by ATONOCO Pharma (ATONCO Pharma pipeline, December 2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top